I'm LongbridgeAI, I can summarize articles.HSBC Global Investment Research issued a research report stating that Johnson & Johnson recently announced the acquisition of Ollin for USD3.325 billion, including an upfront payment of USD2.2 billion and USD1.125 billion in regulatory and commercial milestone payments. Ollin is a partner of INNOVENT BIO (01801.HK) -5.350 (-6.261%) Short selling $243.96M; Ratio 23.276% . The broker maintained its "Buy" rating on INNOVENT BIO (01801.HK) -5.350 (-6.261%) Short selling $243.96M; Ratio 23.276% and raised its TP from HKD130 to HKD133.
INNOVENT BIO (01801.HK) -5.350 (-6.261%) Short selling $243.96M; Ratio 23.276% developed and licensed overseas rights of the VEGF/Ang2 bispecific antibody OLN324 to Ollin for global development. The project is currently undergoing global Phase III studies for eye diseases including diabetic macular edema (DME) and wet age-related macular degeneration (AMD). It marks INNOVENT BIO (01801.HK) -5.350 (-6.261%) Short selling $243.96M; Ratio 23.276% 's first out-licensing deal in ophthalmology with a multinational pharmaceutical company. HSBC Global Investment Research estimated that INNOVENT BIO (01801.HK) -5.350 (-6.261%) Short selling $243.96M; Ratio 23.276% holds about an 8% stake in Ollin and is entitled to a double-digit sales royalty, which could benefit the company and generate recurring income after OLN324 is launched overseas. If Phase III results replicate early-stage data, peak sales of OLN324 could reach USD5 billion.
The broker is also optimistic about the ramp-up in INNOVENT BIO (01801.HK) -5.350 (-6.261%) Short selling $243.96M; Ratio 23.276% 's domestic sales and raised its revenue forecasts for 2026 to 2028 by 2% to 3% to RMB19.8 billion, RMB24.8 billion and RMB29.9 billion, respectively. Among them, GLP-1 revenue is forecast at RMB2.7 billion, RMB4.7 billion and RMB5.4 billion, respectively. Meanwhile, due to effective cost controls, the broker also raised its net profit forecasts by 13% to 20%, expecting net profit to reach RMB2.4 billion, RMB3.6 billion and RMB5 billion, respectively. (gc/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-20 16:25.)
